Cardax IncOOTC CDXI Stock Report

Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii and currently employs 10 full-time employees. The company went IPO on 2012-01-30. The firm has a commercial business unit that markets dietary supplements for inflammatory health. The firm's product platform consists of CDX-101, astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia and CDX-301, the Company’s zeaxanthin pharmaceutical candidate, which is being developed for macular degeneration. The Company’s pharmaceutical candidates are in pre-clinical development, including the planning of investigational new drug (IND) enabling studies. ZanthoSyn is a physician recommended astaxanthin dietary supplement for inflammatory health. The firm sells ZanthoSyn primarily through wholesale and e-commerce channels.